GSK864
- Catalog NO.:A942469
- CAS No. : 1816331-66-4
- Molecular Formula:C30H31FN6O4
- Molecular Weight: 558.61
1. Please click the
![](/usr/uploads/3/201903/xunpan.png.png)
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 1816331-66-4 | Appearance | |
Catalog Number | A942469 | MDL Number | |
Molecular Formula | C30H31FN6O4 | Molecular Weight | 558.61 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | (S)-1-(4-fluorobenzyl)-N3-(4-methoxy-3,5-dimethylphenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3,7-dicarboxamide | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram |
![]() |
||
Signal Word | Warning | UN Number | |
Hazard Statements | Class | ||
Precautionary Statements | Packing Group |
Description
Cabozantinib, also known as XL-184 or BMS-907351, is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several tyrosine receptor kinases. Specifically, cabozantinib appears to have a strong affinity for the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in inhibition of tumor growth and angiogenesis, and tumor regression. Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. |